Persisent ocular hypertension following intravitreal ranibizumab

Bakri, Sophie J.; McCannel, Colin A.; Edwards, Albert O.; Moshfeghi, Darius M.

doi:10.1007/s00417-008-0819-2

Cited by 125 publications

(101 citation statements)

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…74,75 While some patients respond to intravitreal injection with sustained elevation of IOP, most do not even after multiple injections. [76][77][78][79][80][81][82] In our study, we performed intravitreal injection of drug-loaded NS once and observed IOPlowering effects out to 32 days (Fig. 4).…”

Section: Discussionmentioning

confidence: 62%

Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure

Lambert

Carlson

Ende

et al. 2015

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose: We examined the efficacy of an extended-release drug delivery system, nanosponge (NS) encapsulated compounds, administered intravitreally to lower intraocular pressure (IOP) in mice.Methods: Bilateral ocular hypertension was induced in mice by injecting microbeads into the anterior chamber. Hypertensive mice received NS loaded with ocular hypotensive drugs via intravitreal injection and IOP was monitored. Retinal deposition and retinal ganglion cell (RGC) uptake of Neuro-DiO were examined following intravitreal injection of Neuro-DiO-NS using confocal microscopy.Results: Brimonidine-loaded NS lowered IOP 12% to 30% for up to 6 days (P , 0.02), whereas travoprost-NS lowered IOP 19% to 29% for up to 4 days (P , 0.02) compared to saline injection. Three bimatoprost NS were tested: a 400-nm NS and two 700-nm NS with amorphous (A-NS) or amorphous/crystalline (AC-NS) crosslinkers. A single injection of 400 nm NS lowered IOP 24% to 33% for up to 17 days compared to saline, while A-NS and AC-NS lowered IOP 22% to 32% and 18% to 26%, respectively, for up to 32 days (P , 0.046). Over time retinal deposition of Neuro-DiO increased from 19% to 71%; Neuro-DiO released from NS was internalized by RGCs.Conclusions: A single injection of NS can effectively deliver ocular hypotensive drugs in a linear and continuous manner for up to 32 days. Also, NS may be effective at targeting RGCs, the neurons that degenerate in glaucoma.Translational Relevance: Patient compliance is a major issue in glaucoma. The use of NS to deliver a controlled, sustained release of therapeutics could drastically reduce the number of patients that progress to vision loss in this disease.

show abstract

Section: Discussionmentioning

confidence: 62%

Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure

Lambert

Carlson

Ende

et al. 2015

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

show abstract

“…Recent concerns have been raised regarding possible increase in geographic atrophy with anti-VEGF administration, particularly ranibizumab (Grunwald et al 2014(Grunwald et al , 2015. In addition, repeat administration of intravitreal anti-VEGF results in sustained elevation of intraocular pressure in some patients (Bakri et al 2008;Pershing et al 2013;Bakri et al 2014;Dedania and Bakri 2015), suggesting the importance of VEGF to the trabecular meshwork.…”

Section: Rvomentioning

confidence: 99%

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Narayanan

Kuppermann

2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

“…Severe and sustained ocular hypertension Bakri et al [47] reported sustained ocular hypertension as high as 30,34,46, and 50 mmHg in the four patients following 0.5 mg intravitreal ranibizumab for age-related macular degeneration. The elevated IOP persisted across several visits, requiring control with topical glaucoma therapy, and in two cases the addition of a systemic carbonic anhydrase inhibitor.…”

Section: Management Of Na-aionmentioning

confidence: 99%